Get the Stockscreener App
20.41
2.44%
-0.51
After Hours:
20.43
0.02
+0.10%
Forte Biosciences Inc stock is traded at $20.41, with a volume of 242.50K.
It is down -2.44% in the last 24 hours and up +23.55% over the past month.
Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.
See More
Previous Close:
$20.92
Open:
$20.81
24h Volume:
242.50K
Relative Volume:
0.71
Market Cap:
$417.97M
Revenue:
-
Net Income/Loss:
$-75.86M
P/E Ratio:
-3.9966
EPS:
-5.1069
Net Cash Flow:
$-59.39M
1W Performance:
-4.27%
1M Performance:
+23.55%
6M Performance:
-13.00%
1Y Performance:
+49.41%
1-Day Range:
$19.95
$21.59
1-Week Range:
$19.95
$22.39
52-Week Range:
$9.10
$35.80
Forte Biosciences Inc Stock (FBRX) Company Profile
Name
Forte Biosciences Inc
Sector
Industry
Phone
(310) 618-6994
Address
3060 PEGASUS PARK DRIVE, DALLAS, CA
Compare FBRX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FBRX
Forte Biosciences Inc
|
20.41 | 435.17M | 0 | -75.86M | -59.39M | -5.1069 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Forte Biosciences Inc Stock (FBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-25-25 | Initiated | Evercore ISI | Outperform |
| Aug-18-25 | Initiated | Guggenheim | Buy |
| Jan-21-25 | Initiated | TD Cowen | Buy |
| Apr-08-24 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Sep-20-21 | Upgrade | Chardan Capital Markets | Sell → Buy |
| Sep-03-21 | Downgrade | B. Riley Securities | Buy → Neutral |
| Sep-03-21 | Downgrade | Chardan Capital Markets | Buy → Sell |
| Sep-03-21 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Sep-03-21 | Downgrade | Truist | Buy → Hold |
| May-14-21 | Initiated | B. Riley Securities | Buy |
| Mar-26-21 | Initiated | Citigroup | Buy |
| Aug-28-20 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Aug-25-20 | Initiated | Truist | Buy |
View All
Forte Biosciences Inc Stock (FBRX) Latest News
Enterprise value to EBIT forward of Forte Biosciences, Inc. – NASDAQ:FBRX - TradingView
Forte Biosciences, Inc.(NasdaqCM:FBRX) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Forte Biosciences, Inc.(NasdaqCM: FBRX) added to Russell 2500 Growth Benchmark - marketscreener.com
Forte Biosciences, Inc.(NasdaqCM: FBRX) added to Russell 2000 Index - marketscreener.com
Forte Biosciences, Inc.(NasdaqCM:FBRX) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Forte Biosciences, Inc.(NasdaqCM: FBRX) added to Russell 2000 Growth Benchmark - marketscreener.com
Forte Biosciences, Inc.(NasdaqCM: FBRX) added to Russell 3000E Growth Benchmark - marketscreener.com
FBRX Q1 2026 Earnings: EPS Misses Estimates, No Revenue Reported, Stock Gains 2.15%Earnings Deceleration Risk - dars.gov.et
Forte Biosciences Inc (FBRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Forte Biosciences Inc (FBRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Forte Biosciences Inc (FBRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Forte Biosciences Inc (FBRX) Institutional Confidence - TradingKey
Forte Biosciences Inc (FBRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Forte Biosciences (FBRX) CFO receives 22,000 stock options grant - Stock Titan
Forte Biosciences (FBRX) awards 500,000 stock options to insider Wagner - Stock Titan
Forte Biosciences Inc (FBRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Forte Biosciences Inc (FBRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Forte Biosciences Inc (FBRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Forte Biosciences (FBRX) Dips Nearly 5%: Testing Key Support at $16.29Revenue Weighted - newsline.com
One Forte Biosciences Insider Raised Stake By 30% In Previous Year - Yahoo Finance
[EFFECT] Forte Biosciences, Inc. SEC Filing - Stock Titan
FBRX Q1 2026 Earnings: Wider-than-Expected Loss as Biotech Continues DevelopmentMargin Guidance - newsline.com
Trading Systems Reacting to (FBRX) Volatility - Stock Traders Daily
Millennium Group (FBRX) reports shared control of 1,062,182 shares - Stock Titan
Forte Biosciences (FBRX) Edges Lower Amid Sector Volatility, Key Support HoldsSmart Money Flow Stocks - newsline.com
Number of shareholders of Forte Biosciences Inc. – GETTEX:37T - TradingView
Forte Biosciences (FBRX) Slips 1% as Stock Consolidates Between Key Support and ResistanceTrend Continuation Trade - newsline.com
Forte Biosciences (NASDAQ: FBRX) files $500M shelf to sell securities - Stock Titan
Forte Biosciences Shareholders Approve Directors and Governance Items - TipRanks
Forte Biosciences (NASDAQ: FBRX) director receives 18,353 RSU equity award - Stock Titan
Forte Biosciences (NASDAQ: FBRX) files $500M shelf; highlights FB102 clinical wins - Stock Titan
Forte Biosciences (FBRX) director awarded 18,353 restricted stock units in equity grant - Stock Titan
Forte Biosciences (FBRX) director granted 18,353 RSUs in equity award - Stock Titan
Forte Biosciences (FBRX) director awarded 18,353 RSUs vesting after 2026 meeting - Stock Titan
Director at Forte Biosciences (NASDAQ: FBRX) awarded 18,353 RSUs as equity grant - Stock Titan
Forte Biosciences (FBRX) awards 18,353 RSUs to director Steven Kornfeld - Stock Titan
Forte Biosciences (FBRX) stockholders approve amended 2021 equity incentive plan - Stock Titan
FBRX Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Continues Clinical Progress - newsline.com
Forte Biosciences (FBRX) price target increased by 19.72% to 65.02 - MSN
Forte Biosciences Slides As Insider Purchases Lose Another US$70k - simplywall.st
Forte Biosciences Inc stock (US34960P1012): shares slip after recent Q1 loss and high volatility - AD HOC NEWS
FBRX - Finviz
FBRX Q1 2026 Earnings: Pre-Revenue Biotech Reports Narrow EPS Miss Amid Ongoing DevelopmentSurprise Factor Analysis - newsline.com
Forte Biosciences Q1 2026 Earnings: Pre-revenue Biotech Misses EPS Estimates; Stock Dips on Narrower Loss MissTech Earnings Analysis - The Legal Advocate
FBRX Q1 2026 Earnings: Wider-than-Expected Loss Reflects Pre-Revenue Biotech RealityLive Trade Sharing - Newser
Forte Biosciences stock (US34960P1012): Q1 update keeps focus on skin disease pipeline - AD HOC NEWS
(FBRX) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Forte Biosciences Inc stock (US34960P1012): clinical pivot and cash focus keep biotech investors ale - AD HOC NEWS
Forte Biosciences stock (US34960P1012): volatile biotech after recent sell-off tests investor nerves - AD HOC NEWS
Forte Biosciences stock (US34960P1012): New 13G filings highlight major holders - AD HOC NEWS
Forte Biosciences Stock: Targeting Celiac Disease (NASDAQ:FBRX) - Seeking Alpha
Forte Biosciences Inc Stock (FBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Forte Biosciences Inc Stock (FBRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Jan 01 '26 |
Option Exercise |
0.00 |
375 |
0 |
41,895 |
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Dec 30 '25 |
Buy |
26.33 |
9,680 |
254,833 |
41,520 |
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Oct 01 '25 |
Option Exercise |
0.00 |
375 |
0 |
31,974 |
| Wagner Paul A. | SEE REMARKS |
Oct 01 '25 |
Option Exercise |
0.00 |
1,250 |
0 |
82,190 |
0.05%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):